Torrent Pharmaceuticals Ltd
NSE: TORNTPHARM BSE: 500420
₹4078
(0.02%)
Fri, 13 Feb 2026, 08:15 pm
Market Cap1381.34B
PE Ratio64.49
Dividend0.78
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1972
- Incorporated on 15th July as Private Limited Company by Shri Rajnikant C. Patel and family.
1982
- Acquired by Shri Uttamlal N. Mehta in June.
1989
- Became deemed Public Company on 28th June under Section 43-A.
1992
- Amalgamated Torrent Laboratories Limited effective 1st April.
- Became Public Limited Company via Special Resolution on 25th July.
1993
- Merged Torrent Medi-Systems Limited effective 1st April.
- Issued 12,88,400 bonus shares on 7 August in 1:1 ratio.
- Issued 1,25,49,056 bonus shares on 12 November.
1994
- Issued 1,74,144 equity shares to TMSL shareholders.
- First to launch Ranitin, Calcigard, Betacard, Domstal, Dilzem, Cordarone, and Listril.
- Launched Zirtin, Tyklid, Flutamide, and Topcef.
- Created Disease Management Groups.
- Commenced manufacturing of Norfloxacin, Ciprofloxacin, Ranitidine, Atenolol, and Diltiazem.
1995
- Launched Lomef, Dilzem Inj., Depidol LA, Oncoden, Nimotide, and Pefcin.
- Entered strategic alliance with Pfizer Inc.
1996
- Introduced six new drugs including Lozapin.
- Launched Lamitor, Serenata, Tozar, and Syscan eye drops.
- Set up state-of-the-art information management system.
1997
- Formed strategic alliances with Sanofi and Novo Nordisk.
- Established 50:50 JV Sanofi Torrent India.
1998
- Introduced Normabrain 800 and Amlocar.
- Launched Lozapin for resistant schizophrenia.
1999
- Launched Nikoran IV and novel anti-epileptic drug.
2000
- Restructured into three divisions.
- Launched Eurepa (repaglinide).
2001
- Launched Androz (sildenafil citrate).
- Launched De Platt (clopidogrel).
2002
- Launched leflunomide.
- Manufacturing facilities certified with ISO 14001:1996.
- R&D Centre received ISO/IEC 17025:1999 accreditation from NABL.
2003
- Established wholly owned subsidiaries in Germany and Brazil.
- Launched Aripiprazole as Arip MT.
- Received IDMA Quality Excellence Award.
2004
- Launched Ecogat.
- Launched Rozucor.
- Signed agreement with Dr. Reddy's Laboratories for Domstal O.
- Launched Torcoxia (Etoricoxib).
- Launched Symbal (Duloxetine).
2005
- Launched Levetiracetam.
- Acquired Pfizer generic subsidiary in Germany.
- Signed agreement with Novo Nordisk for dedicated insulin formulation facility.
2006
- Received US FDA approval for API and formulations facilities at Indrad.
- Launched AzuCa super-specialty Diabetes division.
- Issued bonus shares in 1:1 ratio.
- Split face value of shares from Rs 10 to Rs 5.
- Launched Nexpro Fast.
- Entered in-licensing deal with Tasly for Cardiotonic pill.
2007
- Launched Fibotab, India's first bulk laxative in tablet form.
- Launched CVpill, world's first polypill in cardiac care.
- Launched Rimoslim, India's first Rimonabant.
2009
- Established new insulin facility for 26 million vials per annum for Novo Nordisk.
2010
- Recommended dividend of Rs. 6 per share.
2011
- Received US FDA approval for alfuzosin hydrochloride extended release tablets.
- Recommended normal dividend of Rs. 6 and special dividend of Rs. 2 per share.
2012
- Appointed Haigreve Khaitan as Additional Director.
- Recommended final dividend of Rs. 2.50 per share.
2013
- Acquired Indian Branded Formulations Business of Elder.
- Recommended bonus shares in 1:1 ratio.
2014
- Entered exclusive licensing agreement with Reliance Life Sciences for 3 biosimilars.
- Received exemption from price control for new FDC product.
2015
- Completed acquisition of Zyg Pharma Pvt Ltd.
- Commenced commercial operations at Dahej plant.
2016
- Launched Adalimumab biosimilar in India.
- Dahej plant received EIR from US FDA.
- Acquired manufacturing unit of Glochem Industries Limited.
2017
- Acquired brands from Novartis AG.
- Acquired Branded Formulation Business of India and Nepal from Unichem Laboratories.
- Expanded insulin manufacturing facility at Indrad with Novo Nordisk.
- Listed amongst top five Fastest Growing Companies by Business World.
2018
- Acquired US-based Bio-Pharm Inc.
2019
- Amended AOA/MOA.
- Signed licensing agreement with Glenmark for co-marketing Remogliflozin Etabonate.
- Changed Registrar & Share Transfer Agent to KFIN TECHNOLOGIES PRIVATE LIMITED.
2021
- USFDA inspection at Levittown manufacturing facility.
- Introduced molnupiravir as Molnutor®.
- Entered Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19.
2022
- Acquired 100% stake in Curatio Health Care Private Limited.
- Recommended bonus shares in 1:1 ratio.
2023
- Signed licensing agreement with Zydus for co-marketing Saroglitazar Mg.
- Started construction of Virochannagar manufacturing facility.
- Received EIR from US FDA for Dahej facility.
2024
- Entered into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals for novel GI drug.
- Commissioned subsidiaries in Colombia and Chile.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800